US rejects experimental painkiller
New York, April 23, 2010
US government advisers have urged regulators to reject an experimental painkiller from King Pharmaceuticals and Acura Pharmaceuticals.
The Acurox pill was designed to discourage abuse by adding the vitamin niacin to the painkiller oxycodone. The companies said people who take multiple pills would get high doses of niacin that could cause uncomfortable flushing.
Members of a Food and Drug Administration (FDA) advisory panel praised the drugmakers for trying to reduce improper use but said they had not shown niacin would be a strong deterrent.
The FDA usually follows panel recommendations when deciding whether to approve new medicines.
King shares closed down 2.8 per cent at $11.10 on the New York Stock Exchange. Acura shares were halted on the Nasdaq while the panel met.-Reuters
More Health & Environment Stories
- NCDs ‘to cost GCC $36bn in 2013’
- Arabtec inks $1.2bn UAE hospital contract
- Infectious disease control ‘urgent need for GCC’
- New HIV cases fall as Bahrain's efforts pay off
- Conference to discuss emergency medicine
- UAE reports 3 more MERS cases
- Bahrain 'free of Mers coronavirus'
- 500,000 suffer from spinal cord injuries
- 3BL to assess Majaal corporate sustainability
- Diabetes experts to meet in Abu Dhabi